dasatinib (Sprycel)
Jump to navigation
Jump to search
Introduction
Tradename: Sprycel
Indications
- chronic myeloid leukemia (CML)
- Philadelphia chromosome + acute lymphoblastic leukemia (ALL)
- for patients not responding to other therapies
Dosage
Tabs: 20, 50, 70, 80, 100, 140 mg[5]
Pharmacokinetics
Adverse effects
- bleeding
- diarrhea
- skin rash
- infections
- headache
- fatigue
- edema
- nausea
- anemia
- neutropenia
- thrombocytopenia
- abnormal liver function tests
- pulmonary hypertension (rare)[3][4]
- pericardial effusion[4]
- pleural effusion[4]
Drug interactions
- levels may be increased by drugs that inhibit cyt P450 3A4
- levels may be decreased by drugs that induce cyt P450 3A4
- St John's wort, carbamazepine, phenobarbital, phenytoin, primidone, others
- proton pump inhibitors may decrease absorption of dasatinib
Mechanism of action
- tyrosine kinase inhibitor
- inhibits proliferation of abnormal leukocytes
- said to act similarly to imatinib (Gleevec)
- may inhibit bcl-abl
- inhibits CSF1R Bristol-Myers Squibb Cost $5000/month 2006
More general terms
References
- ↑ Prescriber's Letter 13(8): 2006 FDA Approves Sprycel, a New Treatment for a Rare Type of Leukemia Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220812&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Cortes JE et al Results of dasatinib therapy in patients with early chronic- phase chronic myeloid leukemia. J Clin Oncol 2010 Jan 20; 28:398. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20008620
- ↑ 3.0 3.1 FDA MedWatch: 10/11/2011 Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm275176.htm
- ↑ 4.0 4.1 4.2 4.3 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 5.0 5.1 dasatinib (Rx) Medscape https://reference.medscape.com/drug/sprycel-dasatinib-342199